Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

MicroVision Is Becoming an Almost Perfect Casino Play

MVIS stock has been all over the map this year. The crazy thing is, this volatility is about the only thing going for MicroVision.

The 7 Best Stocks to Buy If You Think a Market Crash Is Coming

While no one knows for sure whether a market crash will occur, it doesn’t hurt to prepare with these safe and stable stocks to buy.

It’s Really Do or Die for Naked Brand

Some evidence suggests that NAKD stock may have hit a bottom, but this remains one of the riskiest ideas in the market.

Coupang Needs to Focus on Regaining Investor Trust

While Coupang produced strong revenue for its first earnings report as a public company, its growth focus may be a liability.

TPG Pace Beneficial Finance Stock Is Still Risky Despite the Discount

TPGY stock is on a heavy discount but that could be a good reason: EVs simply have a long way to go before becoming mainstream.

Cardano Is Going Rogue Against Bitcoin’s Volatility

While Cardano scores highly on its lack of environmental footprint, for right now, the speculative fervor isn’t considering this.

7 Consumer Staples Stocks to Help Navigate the Uncertainty

While growth stocks provided profitability over the trailing year, the latest rumblings suggest you should rotate into consumer staples.

Zomedica Is Now a Low-Probability Gamble

ZOM stock attracts plenty of attention for its underlying pet care business and its wild potential but this game may be over.

If You Do the Math, Senseonics Makes No Sense

While the underlying science for SENS stock may be a game changer, ultimately, the market does not have the same sentiment.

A Legal Victory for Ripple Labs Isn’t Out of the Question

Although facing an extremely contentious case with the SEC, Ripple Labs might win. Still, it might not matter in the long run.